MASH / MASLD

A new study found physical activity held more weight in the link between the joint exposure of sleep duration, metabolic equivalent of task, and Healthy Eating Index -2015 and MAFLD.

Noureddin explains the discordance between FIB-4 and transient elastography for stratifying fibrosis risk and emphasizes the importance of repetition and attentiveness with FIB-4.

Alkhouri explains the value of AGILE 3+ and AGILE 4, reviewing key findings from a recent study applying the scores to NHANES data to estimate MASLD fibrosis and cirrhosis.

Results suggest discordance between FIB-4 and liver stiffness measurement for MASLD-related fibrosis risk stratification.

Treatment with GLP-1 RAs led to improvements in weight loss, liver function tests, and liver fat in patients with diabetes and MASLD, with hepatic improvements independent of weight loss.

Noureddin reviews key considerations for starting, monitoring, and discontinuing treatment with resmetirom in patients with noncirrhotic MASH.

New expert panel recommendations outline considerations for initiating and monitoring resmetirom treatment in patients with MASH and moderate fibrosis.

Patients with MASH and cirrhosis had a greater prevalence of comorbidities and faced increased annual total health care costs compared to those without cirrhosis.

Findings suggest the current emphasis on targeting inflammation to mitigate fibrosis in MASLD may be incorrect, citing the minimal impact of LBP function loss on fibrosis.

Using NHANES data, researchers calculated AGILE 3 + and AGILE 4 scores to determine the prevalence of advanced fibrosis and cirrhosis in patients with MASLD in the US.

Primary care patients with MASLD who received a prescription for moderate- and high-intensity statins had a lower risk of progressing to a high-risk FIB-4 score.

Findings highlight an increased risk of diabetes, MASLD, and cardiovascular disease in patients with PCOS, with risk varying by PCOS phenotype.

This June 2024 month in review highlights hepatic pipeline developments, new MASH therapeutics on the road to FDA approval, and the latest installment of Qazi Corner.

Phase 2 data presented at EASL showed 52 weeks of treatment with tirzepatide led to MASH resolution with no worsening of fibrosis in patients with MASH and F2/F3 fibrosis.

Survodutide, a glucagon/GLP-1 receptor dual agonist, improved MASH with no worsening of fibrosis, reduced liver fat content, and improved fibrosis by ≥ 1 stage in a phase 2 trial.

Qazi discusses the impact of bariatric surgery on outcomes in patients with decompensated cirrhosis, highlighting its benefit in this patient population.

The retrospective analysis highlights improved outcomes among patients with obesity and a history of bariatric surgery hospitalized with decompensated cirrhosis.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

End-of-study results from the phase 3 REGENERATE study were presented at DDW and highlight obeticholic acid’s trend in benefit for clinical outcomes.

Microbiota differences between individuals with and without MAFLD were associated with dietary intake and clinical outcomes.

Results presented at DDW detail the association between ALT, Fibroscan CAP, Fibroscan VCTE, and histological response to resmetirom in patients enrolled in MAESTRO-NASH.

Results showed metabolic dysfunction was an independent predictor of liver-related events and hepatocellular carcinoma in patients with chronic HCV who achieved SVR.

Results showed poorly controlled HbA1C increased the risk of elevated ALT levels in children and adolescents with type 1 diabetes, suggesting an important link to MASLD.

HBV DNA and HBsAg were not significantly associated with NAFLD in patients with treatment-naïve HBV, but age, BMI, comorbidities, and certain metabolic laboratory parameters were.